电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

MYO18B 抗体 (AA 370-512) (FITC)

This anti-MYO18B antibody is a 兔 多克隆 antibody detecting MYO18B in not_set. Suitable for 人.
产品编号 ABIN7174987
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for MYO18B 抗体 (AA 370-512) (FITC) (ABIN7174987)

抗原

See all MYO18B 抗体
MYO18B (Myosin XVIIIB (MYO18B))

适用

宿主

  • 11
  • 1

克隆类型

  • 11
  • 1
多克隆

标记

  • 4
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This MYO18B antibody is conjugated to FITC

应用范围

请咨询
  • 抗原表位

    AA 370-512

    原理

    MYO18B Antibody, FITC conjugated

    纯化方法

    Protein G purified

    纯度

    >95 %

    免疫原

    Recombinant Human Unconventional myosin-XVIIIb protein (370-512AA)

    亚型

    IgG
  • 限制

    仅限研究用
  • 状态

    Liquid

    缓冲液

    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

    储存液

    ProClin

    注意事项

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    储存条件

    -20 °C,-80 °C

    储存方法

    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 抗原

    MYO18B (Myosin XVIIIB (MYO18B))

    别名

    MYO18B

    背景

    Background: May be involved in intracellular trafficking of the muscle cell when in the cytoplasm, whereas entering the nucleus, may be involved in the regulation of muscle specific genes. May play a role in the control of tumor development and progression, restored MYO18B expression in lung cancer cells suppresses anchorage-independent growth.

    Aliases: BK125H2.1 antibody, DKFZp434C2422 antibody, DKFZp779C1668 antibody, MY18B_HUMAN antibody, MYO18B antibody, myosin 18B antibody, myosin XVIIIB antibody, Myosin-XVIIIb antibody

    UniProt

    Q8IUG5
You are here: